Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Assessing the impact of nutritional status at allogeneic stem cell transplantation on clinical outcomes.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

The Lancet. Haematology·2026
Same author

Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO.

Blood advances·2025
Same author

Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets.

American journal of hematology·2023
Same author

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.

Frontiers in immunology·2022
Same author

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2022

相关实验视频

Updated: Jul 9, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.7K

开发针对复发性/耐火性扩散性大B细胞淋巴瘤的新策略

Eva Gonzalez Barca1

  • 1Hematology Department, Catalan Institute of Oncology-IDIBELL, University of Barcelona, 08908 Barcelona, Spain.

Journal of clinical medicine
|December 9, 2023
PubMed
概括

针对复发性或耐火性扩散性大B细胞淋巴瘤 (DLBCL) 正在开发新疗法,因为目前的疗法对所有患者都不有效. 这篇评论强调了对这种侵略性癌症的有希望的新选择.

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.

背景情况:

  • 扩散性大B细胞淋巴瘤 (DLBCL) 是一种具有显著异质性的侵袭性血液性恶性瘤.
  • 大约40%的DLBCL患者面临疾病复发或对初始化疗免疫疗法的耐药性.
  • 尽管取得了进展,但对于复发性/耐药性 (R/R) DLBCL 的患者,仍然存在着严重的未满足需求.

研究的目的:

  • 审查R/R DLBCL的新兴治疗策略.
  • 突出目前正在临床开发中的新疗法.
  • 为了应对管理R/R DLBCL的持续挑战.

主要方法:

  • 最近的临床试验和研究出版物的文献综述.
  • 专注于R/R DLBCL的新药和治疗方式.
  • 对试验疗法的疗效和安全性数据的分析.

主要成果:

  • 几种新的治疗药物对R/R DLBCL有希望.
  • 已批准的疗法包括抗CD19的CAR T细胞,波拉图祖马布和塔法西他马布.
  • 目前正在进行的研究重点是克服抵抗和改善结果.
关键词:
扩散大的B细胞淋巴瘤.有效性 有效性 有效性.复发/耐火性 复发/耐火性治疗疗法治疗疗法治疗疗法毒性的毒性 毒性的毒性

更多相关视频

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.0K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

相关实验视频

Last Updated: Jul 9, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.7K
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.0K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

结论:

  • 尽管取得了进展,但R/R DLBCL仍然是一个重大的临床挑战.
  • 新兴疗法为那些对当前治疗没有反应的患者提供了新的希望.
  • 持续的研究对于开发更有效的R/R DLBCL治疗至关重要.